Areas of Interest & Competitive Research Grants - Bristol Myers Squibb

Areas of Interest (AOI)

Bristol Myers Squibb seeks Independent Research applications across all therapeutic areas.  Our Areas of Interest outline additional criteria to help guide the scientific community.  All concept applications submitted that best align with our interests will be considered and evaluated. 

Therapeutic Area and / or Compound AOIs Posted on Pre-Concept Submission Period
Start Date End date
Immunology – TYK2 (deucravacitinib) 20-Sep-21 18-Oct-21 19-Nov-21
Oncology – Relatlimab 15-Sept-21  4-Oct-21 29-Oct-21
Immunology – (ozanimod) Ulcerative colitis 31-May-21 31-May-21 23-Jul-21
Hematology 28-May-21 21-Jun-21 23-July-21
Cardiovascular – (mavacamten) Hypertrophic Cardiomyopathy 10-May-21 14-Jun-21 9-Jul-21
Immunology – (ozanimod) Multiple Sclerosis 26-Mar-21 3-May-21 21-May-21


Please note that during an open RFP submission window, clicking on a link to submit your research idea will take you to the FastTrack Investigator Portal and you will receive a message that you are leaving This is part of the normal process.

  • If you are a potential investigator who is interested in seeking support to conduct independent research involving  Nivolumab  in Japan, Taiwan, or Korea, click here
  • If you are a potential investigator who is interested in seeking support for independent research using Apixaban, click here.
  • If you are a potential investigator who is interested in seeking support for non-clinical research using a BMS product, click here
  • If you are a potential investigator who is interested in seeking support for independent research using one of our early pipeline assets, click here
  • If you are a potential investigator who is interested in seeking support for independent research involving NKTR-214 (Bempegaldesleukin) & Nivolumab, click here

Melanoma – Relatlimab ISR Areas of Interest – 2021 RFP Cycle 1


In scope:

  • Relatlimab + Nivolumab or other Relatlimab + Nivolumab-based combinations in metastatic patients with the highest unmet need (i.e., brain metastasis, high LDH, >3 sites of disease, poor PS, post PD1, non-cutaneous, etc.) regardless of BRAF status and line of therapy
  • Understand biomarkers and translational mechanisms of response, resistance, and adverse events to Relatlimab + Nivolumab-based combinations
  • Neoadjuvant/peri-adjuvant research with Relatlimab + nivolumab-based combinations, regardless of BRAF status, to understand tumor biology and improve patient outcomes
  • Sequencing with Relatlimab + Nivolumab relative to other therapies (re-treatment and switch), regardless of BRAF status

Out of scope:

  • Pediatric studies
  • Studies investigating non-melanoma tumors
  • Studies investigating Relatlimab as monotherapy
  • Studies only including Nivolumab ± Ipilimumab in melanoma (Nivolumab ± Ipilimumab as comparator arm allowed)
  • Each individual drug in Relatlimab + Nivolumab-based combination must have established phase 2 dose, otherwise considered out of scope

TYK2 (deucravacitinib) AOIs – RFP#2


In scope

  • Deucravacitinib efficacy and safety in moderate to severe psoriasis, including patient sub-populations
  • Demographics (e.g., ethnicity, race) 
  • Body regions
  • Psoriasis treatments (e.g., Systemic treatment naïve, switching from or adding on to topical therapy, switching from other oral systemic therapies
  • Additional measures of response (eg, patient satisfaction, other Patient-Reported Outcomes)
  • Clinical and biomarker proof-of-concept evidence with deucravacitinib in other dermatological immune-mediated diseases with evidence of involvement of TYK2-mediated pathways
  • Nonclinical studies furthering the understanding of the role of TYK2 in immune mediated diseases

Out of scope

  • Pediatric studies
  • Combination with other disease modifying therapies 
  • Alternative dosing regimens


  • Based on the current manufacturing capacity for CAR T products, we are unable to consider ISR proposals that require the provision of CAR T product at this time. 
  • We are accepting ISR proposals for CAR T based on the following Areas of Interest (AOIs)

Liso-cel AOIs

  1. Decipher the optimal treatment sequence with liso-cel in DLBCL through real world evidence
    • What is the optimal sequencing of liso-cel with other available treatments?
    • What are the outcomes for patients who proceed to other therapies post liso-cel failure? 
  2. Identify optimal bridging strategies to liso-cel in DLBCL including through real world evidence 
  3. Evaluate outcomes in patients treated with liso-cel or other CAR T through real world evidence 
    • What are the outcomes in the commercial setting vs clinical trials?
    • What are the outcomes for those who do not experience grade 3+ CRS / NT, or other AEs?
    • Do interventions for CRS / NT (e.g., steroids, tocilizumab) impact outcomes?

Ide-cel AOIs

  1. Evaluate use of ide-cel in triple class exposed RRMM through real world evidence
    • Evaluate predictors of response
    • Assess impact of bridging therapy
    • Understand longer-term outcomes with ide-cel
  2. Evaluate safety profile to inform setting of care decisions through real world evidence
    • Assess mitigation and monitoring strategies for CRS & NT
    • Evaluate site of care and timing of release from hospital
    • Assess impact of long-term cytopenias
  3. Evaluate sequencing in RRMM through real world evidence
    • Assess sequencing of ide-cel with respect to other anti-BCMA assets
    • Evaluate impact of prior treatments 
    • Assess outcomes of patients who receive other therapies post ide-cel failure

If you are an investigator who is interested in seeking support for independent research relating to CAR T (ide-cel or liso-cel), click here

Please click on the product name to see the Full U.S. Prescribing Information for ELIQUIS®, EMPLICITI, NULOJIX®, OPDIVO®, ORENCIA®, SPRYCEL®, YERVOY®, including Boxed WARNINGS for ELIQUIS®, NULOJIX®, and Boxed WARNING for YERVOY® regarding immune-mediated adverse reactions.

Begin a New Application